Goldfinch Bio Initiates Phase 1 Clinical Trial of GFB-024, a Novel Precision Medicine Product Candidate for Patients with Severe Insulin Resistant Diabetic Nephropathy (DN)

Voyager Therapeutics Presents New Preclinical Data Showing Reduction Of Pathological Tau With Vectorized Anti-Tau Antibody

Magenta Therapeutics Announces $86.4 Million Common Stock Investment From Multiple Investors

Magenta Therapeutics Announces Positive Preliminary Results From Phase 2 Clinical Trial Of MGTA-145 In Multiple Myeloma And Provides An Update On Its Anticipated Clinical Study With MGTA-117

Fulcrum Therapeutics Announces U.S. Food and Drug Administration Grants Fast Track Designation to Losmapimod for the Potential Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)